Navigation Links
VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting

ular Edema (DME) is the most prevalent cause of moderate vision loss in patients with diabetes. DME is a common complication of Diabetic Retinopathy (DR), a disease affecting the blood vessels of the retina. A leading cause of blindness in younger adults (under 50), DME occurs when fluid leaks into the center of the macula, the light-sensitive part of the retina responsible for sharp, direct vision. Fluid in the macula can cause severe vision loss or blindness.

Approximately 500,000 Americans currently suffer from DME, with 75,000 new cases arising each year. According to the American Diabetes Association, more than 18 million Americans currently suffer from diabetes and many other people are at risk for developing diabetes. With the incidence of diabetes steadily climbing, it is projected that up to 10 percent of all patients with diabetes will develop DME during their lifetime.

About Regeneron Pharmaceuticals

Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.

This news release discusses historical information and includes forward-looking statements about Regeneron and its products, programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of our drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize our drug candidates, competing drugs that are superior to our product candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agr
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: VEGF Trap Eye Phase Wet AMD Results Reported ARVO Annual Meeting
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... Yesterday, former Congressman Patrick Kennedy ... facility. Rep. Kennedy and Dick Moberg ... research in neurological disease and treatment. ... Garen Staglin , created One Mind, a ... that will radically accelerate the development and implementation ...
(Date:7/10/2014)... 2014   LabStyle Innovations Corp . (OTCQB:DRIO), developer ... the appointment of Professor Richard B. Stone ... of Directors. Prof. Stone brings over ... LabStyle as an entrepreneur, venture capitalist public, company ... expert. He currently serves on the board of ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... half of,health care workers get an annual flu shot, ... and the federal Centers for Disease,Control of the need ... is plenty of vaccine available this season, so there ... shot," said Joanne Grossi, deputy,secretary for health promotion and ...
... COGENT Trials To Enroll 4,000 Patients Worldwide, ... announced today it is launching a global Phase ... of its novel combination therapy CGT-2168.,The program, which ... 4,000 patients at hundreds of sites in the ...
Cached Medicine Technology:State, Federal Officials Remind Health Care Workers, Other at-Risk Individuals to Get Annual Flu Shot 2Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy 2
(Date:7/12/2014)... (PRWEB) July 12, 2014 For those who ... bodies can readily absorb the nutrients in food. The enzymes ... that are small enough to be absorbed by human bodies. ... a lack of enzymes in regular food is the cause ... product that was started by Michelle DelPresto, a mother of ...
(Date:7/12/2014)... Salt Lake City, Utah (PRWEB) July 12, 2014 ... Five spotlighted two types of startups, with awards being ... UVEF’s new emphasis spotlighted Utah’s outstanding entrepreneur community with ... are proving a sustainable model with incoming revenue. , ... companies from across the state that are under 5 ...
(Date:7/12/2014)... 2014 Restore My Vision Today is ... Pearson, a couple boasting very impressive credentials on the ... Vision Today as a way to help consumers do ... in their respective patients’ treatments . , ... “secret” trove of pertinent information relevant to eye care ...
(Date:7/11/2014)... MagicQuinceaneraDresses.com, the popular online supplier of special occasion gowns, ... dresses . The company’s new items are specially designed ... a large amount of money. They are all available ... company’s online shop has become a one stop platform ... addition to exquisite Quinceanera dresses, it also offers great ...
(Date:7/11/2014)... July 11, 2014 As transvaginal ... against Johnson & Johnson’s Ethicon Inc. unit continue ... notes that the Texas Attorney General’s Office has ... of surgical mesh products used to treat pelvic ... a report from kens5.com, the probe began nearly ...
Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4
... Onchocerciasis, river blindness or craw craw is endemic to ... weakening// in affected individuals thus rendering them listless and ... the economy of this area. The disease is caused ... the bite of the black fly, Simulium. ...
... study published by scientists from California University in the ... re-evaluation//. Scientist have discovered that the virus evaded ... intestinal tissue of patients, where it continued to replicate ... showed that the antiretrovirals were working. ...
... iodine dose to cure deadly brain tumors such as ... is used as carriers for radioactive iodine. The first ... was conducted by under Adam N. Mamelak, M.D., a ... About 18 patients participated in the trial and it ...
... patient was discharged for a week after undergoing successful surgery, ... Guoxing, 30, who had not seen his wife and two ... returned home Friday for a week-long visit to his family ... his face is alive and Li has been doing well, ...
... – The accomplishments of Thailand and Cambodia in the ... achieved primarily through the extensive use of condoms.// ... Singapore's Ministry of Health, said "The 100 per cent ... prominent examples of successful prevention efforts." ,In ...
... been the cornerstones of managing type 2 diabetes. But ... ,Now, a new systematic review shows that exercise ... sensitivity to insulin, and decreases blood lipids (fats) while ... 2 diabetes is an increasing problem in Western societies ...
Cached Medicine News:Health News:Onchocerciasis: Presentation And Treatment 2Health News:New Carrier Developed To Deliver Drugs to Gliomas 2Health News:New Carrier Developed To Deliver Drugs to Gliomas 3Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 2Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 3
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
BD Vacutainer® Specialty Tubes - Other - Glass...
BD Vacutainer® Specialty Tubes - Other - Plastic...
BD Vacutainer® Specialty Tubes - Lead Testing...
Medicine Products: